Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation

• Published in: Clinical gastroenterology and hepatology Vol. 19; no. 12; pp. 2499 - 2513
• Main Authors: Wu, Shanshan, Zeng, Na, Sun, Feng, Zhou, Jialing, Wu, Xiaoning, Sun, Yameng, Wang, Bingqiong, Zhan, Siyan, Kong, Yuanyuan, Jia, Jidong, You, Hong, Yang, Hwai-I
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2021
• Subjects: Antiviral Agents - therapeutic use; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - drug therapy; Chronic Hepatitis B; Cohort Studies; External Validation; Gastroenterology and Hepatology; Hepatitis B, Chronic - complications; Hepatitis B, Chronic - drug therapy; Hepatocellular Carcinoma; Humans; Liver Neoplasms - diagnosis; Liver Neoplasms - drug therapy; Meta-Analysis; Prediction Model; Risk Factors; Chronic Hepatitis B; Meta-Analysis; Prediction Model; BFH; E; CI; HBeAg; LSM; ALT; AUROC; HCC; AFP; O; BS; External Validation; ALB; PLT; CHB; HBV; Hepatocellular Carcinoma; hepatitis B virus; alanine aminotransferase; hepatitis B e antigen; observed; area under the receiver-operating characteristic curve; α-fetoprotein; Beijing Friendship Hospital; liver stiffness measurement; expected; Brier score; albumin; platelet; confidence interval
• DOI: 10.1016/j.cgh.2021.02.040
• ISSN: 1542-3565; 1542-7714

The aim of our study was to characterize the performance of hepatocellular carcinoma (HCC) prediction models in chronic hepatitis B (CHB) patients through meta-analysis followed by external validation. We performed a systematic review and meta-analysis of current literature, followed by external validation in independent multi-center cohort with 986 patients with CHB undergoing entecavir treatment (median follow-up: 4.7 years). Model performance to predict HCC within 3, 5, 7, and 10 years was assessed using area under receiver operating characteristic curve (AUROC) and calibration index. Subgroup analysis were conducted by treatment status, cirrhotic, race and baseline alanine aminotransferase. We identified 14 models with 123,885 patients (5,452 HCC cases), with REACH-B, CU-HCC, GAG-HCC, PAGE-B and mPAGE-B models being broadly externally validated. Discrimination was generally acceptable for all models, with pooled AUC ranging from 0.70 (95% CI, 0.63-0.76 for REACH-B) to 0.83 (95% CI, 0.78-0.87 for REAL-B) for 3-year, 0.68 (95% CI, 0.64-0.73 for REACH-B) to 0.81 (95% CI, 0.77-0.85 for REAL-B) for 5-year and 0.70 (95% CI, 0.58-0.80 for PAGE-B) to 0.81 (95% CI, 0.78-0.84 for REAL-B and 0.77-0.86 for AASL-HCC) for 10-year prediction. However, calibration performance was poorly reported in most studies. In external validation cohort, REAL-B showed highest discrimination with 0.76 (95% CI, 0.69-0.83) and 0.75 (95% CI, 0.70-0.81) for 3 and 5-year prediction. The REAL-B model was also well calibrated in the external validation cohort (3-year Brier score 0.066). Results were consistent in subgroup analyses. In a systematic review of available HCC models, the REAL-B model exhibited best discrimination and calibration.